Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (161-170 of 436) with videos related to

Pageof 44
Sort By:
Journal of Thrombosis and Thrombolysis|January 25, 2012
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopeniaJames W Wisler, Jeffrey B Washam, Richard C Becker
Journal of Thrombosis and Thrombolysis|April 20, 2006
Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusionsKatie M Twomley, Sunil V Rao, Richard C Becker
Journal of Thrombosis and Thrombolysis|July 13, 2013
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillationSean D Pokorney, Matthew W Sherwood, Richard C Becker
Cardiology in Review|October 16, 2009
Cardiac rupture after myocardial infarction: new insights from murine modelsDavid C Sane, Willis Scott Mozingo, Richard C Becker
Chest|March 3, 2011
Beyond thrombosis: the versatile platelet in critical illnessJason N Katz, Kamalkumar P Kolappa, Richard C Becker
Journal of Thrombosis and Thrombolysis|April 26, 2003
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistanceYouFu Li, Miguel Rodriquez, Frederick A Spencer, et al.
Frontiers in Physiology|December 11, 2020
A Novel Homozygous Intronic Variant in TNNT2 Associates With Feline CardiomyopathyJames W McNamara, Maggie Schuckman, Richard C Becker, et al.
Annals of the New York Academy of Sciences|October 3, 2009
Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factorRichard C Becker, Sabah Oney, Kristian C D Becker, et al.
American Heart Journal|March 3, 2015
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trialsArun Krishnamoorthy, Matthew W Sherwood, Renato D Lopes, et al.
Thrombosis and Haemostasis|December 8, 2004
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular diseaseRichard C Becker, John Alexander, Christopher K Dyke, et al.
Pageof 44

Showing results (161-170 of 436) with videos related to

Sort By:
Pageof 44
Journal of Thrombosis and Thrombolysis|January 25, 2012
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopeniaJames W Wisler, Jeffrey B Washam, Richard C Becker
Journal of Thrombosis and Thrombolysis|April 20, 2006
Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusionsKatie M Twomley, Sunil V Rao, Richard C Becker
Journal of Thrombosis and Thrombolysis|July 13, 2013
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillationSean D Pokorney, Matthew W Sherwood, Richard C Becker
Cardiology in Review|October 16, 2009
Cardiac rupture after myocardial infarction: new insights from murine modelsDavid C Sane, Willis Scott Mozingo, Richard C Becker
Chest|March 3, 2011
Beyond thrombosis: the versatile platelet in critical illnessJason N Katz, Kamalkumar P Kolappa, Richard C Becker
Journal of Thrombosis and Thrombolysis|April 26, 2003
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistanceYouFu Li, Miguel Rodriquez, Frederick A Spencer, et al.
Frontiers in Physiology|December 11, 2020
A Novel Homozygous Intronic Variant in TNNT2 Associates With Feline CardiomyopathyJames W McNamara, Maggie Schuckman, Richard C Becker, et al.
Annals of the New York Academy of Sciences|October 3, 2009
Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factorRichard C Becker, Sabah Oney, Kristian C D Becker, et al.
American Heart Journal|March 3, 2015
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trialsArun Krishnamoorthy, Matthew W Sherwood, Renato D Lopes, et al.
Thrombosis and Haemostasis|December 8, 2004
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular diseaseRichard C Becker, John Alexander, Christopher K Dyke, et al.
Pageof 44